The Capitol Hill rag Roll Call is just as flummoxed as I am over the Janssen/ Johnson and Johnson Covid vaccine being produced by Emergent BioSolutions. The FDA told them to ask J and J about it, but J and J declined to answer. Below is the first part of a long article that in the end tells you very little.
However, disgraced Robert Kadlec, former Asst Sec for Preparedness and Emergency Response who gave more contracts to Emergent (his former client) than to any other company, and couldn’t afford to procure a machine that made N95 masks nor buy masks or PPE because he was wasting his billions on anthrax and smallpox vaccines from Emergent–well, he is back in business on the Hill.
Kadlec got a job with disgraced Senator Burr, the Pharma industry Senator who was investigated for insider trading last February 2020, after getting secret briefings about the pandemic. Cronies who play together, stay together.
From Roll Call:
A pharmaceutical contractor under scrutiny for its ties to former government officials could be one of the bottlenecks holding up the production of millions of Johnson & Johnson COVID-19 vaccines.
Emergent BioSolutions, the U.S. company making “drug substance,” the active ingredient in the vaccines, is still awaiting regulatory approval, according to a person familiar with the process. Emergent-made doses were not included in the paperwork Johnson & Johnson submitted to the Food and Drug Administration.
Johnson & Johnson is due to deliver 20 million doses by the end of March, but just 4.7 million have been delivered, according to the Centers for Disease Control and Prevention.
The FDA declined to respond to questions, directing questions to Johnson & Johnson.
“We expect to ship 20 million doses by the end of March,” Johnson & Johnson spokesperson Jake Sargent said in an email, declining to share details on when supply will begin to ramp up and to what degree the delay is related to Emergent….